You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Aro Biotherapeutics Names Cancer Biologist McMahon and Protein Structure and Design Expert Swanson to its Scientific Advisory Board
Login
Username:

Password:


Related Headlines

Novartis to build new radioligand therapy site in Texas

Epredia signs EU distribution deal with Mindpeak for AI pathology software

Astellas Pharma signs global strategic collaboration with Vir Biotechnology

Illumina sets out 18-Month NovaSeq X roadmap to boost sequencing performance and scale

Gilead to acquire Arcellx to gain full control of anito-cel

AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL

CStone Pharmaceuticals' sugemalimab granted new indication by UK MHRA

FDA accepts Genentech application for giredestrant combination in ESR1-mutated advanced breast cancer

EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer

IBA and Shreeji sign agreement to deploy four cyclotrons for PET radiopharmaceuticals in India

AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study

Liminatus Pharma prices USD4.0m public offering

First Ascent Biomedical opens Functional Precision Medicine cancer lab in Miami

Nucleome Therapeutics names new chief scientific officer

Eli Lilly and Company reports positive Phase 3 LIBRETTO-432 results for Retevmo in early-stage RET fusion-positive NSCLC

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026